Cube Labs SpA MIL:CUBE:
UNIT LIPOVEXA OBTAINS U.S. PATENT FOR NEW THERAPEUTIC PLATFORM FOR TREATMENT OF METABOLIC DISORDERS
Further company coverage:
Cube Labs Unit Lipovexa Obtains U.S. Patent For New Therapeutic Platform For Treatment Of Metabolic Disorders
Earlier from Cube Labs
- Cube Labs Renews Strategic Partnership With INBB
- Cube Labs Concludes Capital Hike Option Offer, Shares Subscribed For EUR 0.4 Mln
- Italy - Factors to watch on October 27
- Cube Labs To Execute Capital Hike For Up To EUR 5 Mln